α-Galactosylceramide and Novel Synthetic Glycolipids Directly Induce the Innate Host Defense Pathway and Have Direct Activity against Hepatitis B and C Viruses
| Autor: | Bertha Conyers, Timothy M. Block, Lijuan Wang, Anand Mehta, Robert M. Moriarty, Raymond A. Dwek, Baohua Gu, Serguey Ouzounov |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Hepatitis B virus
Cell Survival Hepatitis C virus Hepacivirus Transgene Blotting Western Molecular Sequence Data Galactosylceramides medicine.disease_cause Antiviral Agents Cell Line Microbiology Mice Viral Proteins Glycolipid medicine Animals Humans Pharmacology (medical) Inducer Pharmacology biology Interferon-beta Hepatitis B biology.organism_classification medicine.disease Virology Immunity Innate Porifera Infectious Diseases Carbohydrate Sequence Cell culture DNA Viral Glycolipids |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 48:2085-2090 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.48.6.2085-2090.2004 |
| Popis: | α-Galactosylceramide is a glycolipid derived from marine sponges that is currently in human clinical trials as an anticancer agent. It has also been shown to be effective in reducing the amount of hepatitis B virus (HBV) DNA detected in mice that produce HBV constitutively from a transgene. It was assumed that all of the antiviral and antitumor activities associated with α-galactosylceramide were mediated through the activation of NK T cells. However, we report here an additional unpredicted activity of α-galactosylceramide as a direct antiviral agent and inducer of the innate host defense pathway. To exploit this activity, we have developed a new class of smaller, orally available glycolipids that also induce the innate host defense pathway and have direct activity against HBV and hepatitis C virus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|